GB8904161D0
(en)
*
|
1989-02-23 |
1989-04-05 |
Hoffmann La Roche |
Substituted pyrroles
|
MC2096A1
(fr)
*
|
1989-02-23 |
1991-02-15 |
Hoffmann La Roche |
Pyrroles substitues
|
PT93947B
(pt)
*
|
1989-05-05 |
1996-11-29 |
Goedecke Ag |
Processo para a preparacao de novos derivados de maleinimidas e de composicoes farmaceuticas que os contem
|
US5380746A
(en)
*
|
1989-05-05 |
1995-01-10 |
Goedecke Aktiengesellschaft |
Bis-(1H-indol-3-YL)-maleinimide derivatives, processes for the preparation thereof and pharmaceutical compositions containing them
|
DE3914764A1
(de)
*
|
1989-05-05 |
1990-11-08 |
Goedecke Ag |
Maleinimid-derivate und deren verwendung als arzneimittel
|
DE4005970A1
(de)
*
|
1990-02-26 |
1991-08-29 |
Boehringer Mannheim Gmbh |
Neue trisubstituierte maleinimide, verfahren zu ihrer herstellung sowie arzneimittel, die diese verbindungen enthalten
|
DE4005969A1
(de)
*
|
1990-02-26 |
1991-08-29 |
Boehringer Mannheim Gmbh |
Neue trisubstituierte pyrrole, verfahren zu ihrer herstellung sowie arzneimittel, die diese verbindungen enthalten
|
US5292747A
(en)
*
|
1990-08-07 |
1994-03-08 |
Hoffman-La Roche Inc. |
Substituted pyrroles
|
CA2046801C
(en)
*
|
1990-08-07 |
2002-02-26 |
Peter D. Davis |
Substituted pyrroles
|
GB9123396D0
(en)
*
|
1991-11-04 |
1991-12-18 |
Hoffmann La Roche |
A process for the manufacture of substituted maleimides
|
EP0630241A1
(en)
*
|
1992-03-20 |
1994-12-28 |
The Wellcome Foundation Limited |
Indole derivatives with antiviral activity
|
US5290777A
(en)
*
|
1993-02-24 |
1994-03-01 |
Regents Of The Univ. Of California |
Use for topsentin compounds and pharmaceutical compositions containing same
|
AU678435B2
(en)
*
|
1993-05-10 |
1997-05-29 |
F. Hoffmann-La Roche Ag |
Substituted pyrroles
|
US5721230A
(en)
*
|
1993-05-10 |
1998-02-24 |
Hoffmann-La Roche Inc. |
Substituted pyrroles
|
US5405864A
(en)
*
|
1993-10-15 |
1995-04-11 |
Syntex (U.S.A.) Inc. |
Chemotherapeutic maleimides
|
TW270114B
(sv)
*
|
1993-10-22 |
1996-02-11 |
Hoffmann La Roche |
|
YU49200B
(sh)
*
|
1993-12-07 |
2004-09-03 |
Eli Lilly And Company |
Inhibitori proteinske kinaze c
|
US5843935A
(en)
*
|
1993-12-07 |
1998-12-01 |
Eli Lilly And Company |
Protein kinase C inhibitors
|
US5624949A
(en)
*
|
1993-12-07 |
1997-04-29 |
Eli Lilly And Company |
Protein kinase C inhibitors
|
JPH07238044A
(ja)
*
|
1993-12-07 |
1995-09-12 |
Eli Lilly & Co |
ビスインドリルマレイミドの改良合成法
|
US5541347A
(en)
*
|
1993-12-07 |
1996-07-30 |
Eli Lilly And Company |
Synthesis of bisindolylmaleimides
|
US5723456A
(en)
*
|
1993-12-07 |
1998-03-03 |
Eli Lilly & Company |
Therapeutic treatment for cardiovascular diseases
|
PT817627E
(pt)
*
|
1993-12-23 |
2005-07-29 |
Lilly Co Eli |
Inibidores da proteina cinase c
|
US5545636A
(en)
*
|
1993-12-23 |
1996-08-13 |
Eli Lilly And Company |
Protein kinase C inhibitors
|
WO1995034307A1
(en)
*
|
1994-06-14 |
1995-12-21 |
Sloan-Kettering Institute For Cancer Research |
Ceramide-activated protein kinase and methods of use of effectors
|
US5491242A
(en)
*
|
1994-06-22 |
1996-02-13 |
Eli Lilly And Company |
Protein kinase C inhibitors
|
US5481003A
(en)
*
|
1994-06-22 |
1996-01-02 |
Eli Lilly And Company |
Protein kinase C inhibitors
|
DK0695755T3
(da)
*
|
1994-08-04 |
1999-06-28 |
Hoffmann La Roche |
Pyrrolocarbazoler
|
US5705511A
(en)
*
|
1994-10-14 |
1998-01-06 |
Cephalon, Inc. |
Fused pyrrolocarbazoles
|
US5475110A
(en)
*
|
1994-10-14 |
1995-12-12 |
Cephalon, Inc. |
Fused Pyrrolocarbazoles
|
US5594009A
(en)
*
|
1994-10-14 |
1997-01-14 |
Cephalon, Inc. |
Fused pyrrolocarbazoles
|
US5591855A
(en)
*
|
1994-10-14 |
1997-01-07 |
Cephalon, Inc. |
Fused pyrrolocarbazoles
|
US5559228A
(en)
*
|
1995-03-30 |
1996-09-24 |
Eli Lilly And Company |
Synthesis of bisindolylmaleimides
|
AU6836696A
(en)
*
|
1995-09-05 |
1997-03-27 |
Banyu Pharmaceutical Co., Ltd. |
Antitumor indolopyrrolocarbazole derivatives
|
NZ323571A
(en)
*
|
1995-11-20 |
1998-12-23 |
Lilly Co Eli |
Protein kinase c inhibitor
|
US5616724A
(en)
*
|
1996-02-21 |
1997-04-01 |
Cephalon, Inc. |
Fused pyrrolo[2,3-c]carbazole-6-ones
|
CA2249205A1
(en)
*
|
1996-03-20 |
1997-09-25 |
Eli Lilly And Company |
Synthesis of indolylmaleimides
|
US6232299B1
(en)
|
1996-05-01 |
2001-05-15 |
Eli Lilly And Company |
Use of protein kinase C inhibitors to enhance the clinical efficacy of oncolytic agents and radiation therapy
|
UA54427C2
(uk)
*
|
1996-05-01 |
2003-03-17 |
Елі Ліллі Енд Компані |
Спосіб лікування очних захворювань, які пов'язані з фактором васкулярного ендотеліального росту
|
CA2253608A1
(en)
|
1996-05-01 |
1997-11-06 |
Louis Vignati |
Therapeutic treatment for vegf related diseases
|
PE91598A1
(es)
|
1996-07-29 |
1998-12-24 |
Hoffmann La Roche |
Pirroles sustituidos
|
PE91498A1
(es)
*
|
1996-07-29 |
1998-12-22 |
Hoffmann La Roche |
Pirroles sustituidos
|
PE91698A1
(es)
*
|
1996-07-29 |
1998-12-24 |
Hoffmann La Roche |
Pirroles sustituidos
|
US6093709A
(en)
*
|
1996-08-22 |
2000-07-25 |
Eli Lilly And Company |
Therapeutic treatment for sexual dysfunctions
|
HUP0003203A3
(en)
*
|
1996-08-23 |
2002-01-28 |
Lilly Co Eli |
Process for producing bisindolymalimides
|
US5962446A
(en)
*
|
1996-08-30 |
1999-10-05 |
Eli Lilly And Company |
Therapetutic treatment for human T cell lymphotrophic virus type 1 infection
|
US6107327A
(en)
*
|
1996-08-30 |
2000-08-22 |
Eli Lilly And Company |
Therapeutic treatment for HIV infection
|
SE9603283D0
(sv)
*
|
1996-09-10 |
1996-09-10 |
Astra Ab |
New compounds
|
SE9603284D0
(sv)
*
|
1996-09-10 |
1996-09-10 |
Astra Ab |
New compounds
|
TW472045B
(en)
*
|
1996-09-25 |
2002-01-11 |
Astra Ab |
Protein kinase C inhibitor compounds, method for their preparation, pharmaceutical composition thereof and intermediate used for their preparation
|
ES2212814T3
(es)
*
|
1996-10-31 |
2004-08-01 |
Harbor Branch Oceanographic Institution, Inc. |
Uso de compuestos y composiciones antiinflamatorias neurogenicas.
|
US5859261A
(en)
*
|
1997-03-20 |
1999-01-12 |
Eli Lilly And Company |
Synthesis of indolylmaleimides
|
US6093740A
(en)
*
|
1997-04-30 |
2000-07-25 |
Eli Lilly And Company |
Therapeutic treatment for skin disorders
|
US6133452A
(en)
*
|
1997-08-22 |
2000-10-17 |
Eli Lilly And Company |
Synthesis of bisindolylmalimides
|
AR017200A1
(es)
|
1997-12-23 |
2001-08-22 |
Astrazeneca Ab |
Compuestos inhibidores de la proteina cinasa c, sales farmaceuticamente aceptables de los mismos, formulaciones farmaceuitcas que los comprenden, usode las mismas y proceso para la sintesis de dichos compuestos
|
AU2548699A
(en)
*
|
1998-02-23 |
1999-09-06 |
Rei Asakai |
Cell death inhibitors
|
US6103713A
(en)
*
|
1998-03-05 |
2000-08-15 |
Eli Lilly And Company |
Therapeutic treatment for autoimmune diseases
|
US6291446B1
(en)
|
1998-03-05 |
2001-09-18 |
Eli Lilly And Company |
Therapeutic treatment for cytomegalovirus infection
|
US6103712A
(en)
*
|
1998-03-05 |
2000-08-15 |
Eli Lilly And Company |
Therapeutic treatment for asthma
|
US6225301B1
(en)
|
1998-03-05 |
2001-05-01 |
Eli Lilly And Company |
Therapeutic treatment for renal dysfunction
|
SE9800835D0
(sv)
|
1998-03-13 |
1998-03-13 |
Astra Ab |
New Compounds
|
CZ299068B6
(cs)
*
|
1998-03-17 |
2008-04-16 |
F. Hoffmann-La Roche Ag |
Substituovaný bisindolylmaleinimid a farmaceutický prostredek s jeho obsahem
|
SE9802538D0
(sv)
*
|
1998-07-13 |
1998-07-13 |
Astra Ab |
New pharmaceutically active compounds
|
US6350786B1
(en)
†
|
1998-09-22 |
2002-02-26 |
Hoffmann-La Roche Inc. |
Stable complexes of poorly soluble compounds in ionic polymers
|
US6719520B2
(en)
|
1998-10-08 |
2004-04-13 |
Smithkline Beecham Corporation |
Method and compounds
|
EP1119548B1
(en)
*
|
1998-10-08 |
2004-12-08 |
SmithKline Beecham plc |
3-(3-chloro-4-hydroxyphenylamino)-4-(2-nitrophenyl)-1h-pyrrole-2,5-dione as glycogen synthase kinase-3 inhibitor (gsk-3)
|
GB9828640D0
(en)
*
|
1998-12-23 |
1999-02-17 |
Smithkline Beecham Plc |
Novel method and compounds
|
DE60005493T2
(de)
*
|
1999-03-31 |
2004-07-01 |
Vernalis Ltd., Wokingham |
Pyrimido[6,1-a]isochinolinonderivate
|
US6492406B1
(en)
|
1999-05-21 |
2002-12-10 |
Astrazeneca Ab |
Pharmaceutically active compounds
|
US6284783B1
(en)
|
1999-06-09 |
2001-09-04 |
The Uab Research Foundation |
Use of bisindolylmaleimide compounds to induce Fas-mediated apoptosis
|
US6346625B1
(en)
|
1999-06-23 |
2002-02-12 |
Astrazeneca Ab |
Protein kinase inhibitors
|
EP1224932A4
(en)
*
|
1999-08-20 |
2002-10-16 |
Sagami Chem Res |
DRUGS INHIBITING CELL DEATH
|
US6559164B1
(en)
|
1999-10-12 |
2003-05-06 |
Hoffmann-La Roche Inc. |
Substituted pyrroles suitable for continuous infusion
|
US6313143B1
(en)
*
|
1999-12-16 |
2001-11-06 |
Hoffmann-La Roche Inc. |
Substituted pyrroles
|
US6281356B1
(en)
|
1999-12-22 |
2001-08-28 |
Hoffmann-La Roche Inc. |
Substituted pyrroles
|
GB0008264D0
(en)
*
|
2000-04-04 |
2000-05-24 |
Smithkline Beecham Plc |
Novel method and compounds
|
US6326501B1
(en)
*
|
2000-04-19 |
2001-12-04 |
Hoffmann-La Roche Inc. |
Methylation of indole compounds using dimethyl carbonate
|
US7129250B2
(en)
*
|
2000-05-19 |
2006-10-31 |
Aegera Therapeutics Inc. |
Neuroprotective and anti-proliferative compounds
|
CA2308994A1
(en)
*
|
2000-05-19 |
2001-11-19 |
Aegera Therapeutics Inc. |
Neuroprotective compounds
|
US6353007B1
(en)
*
|
2000-07-13 |
2002-03-05 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Substituted 1-(4-aminophenyl)indoles and their use as anti-inflammatory agents
|
WO2002010158A2
(en)
|
2000-07-27 |
2002-02-07 |
F. Hoffmann-La Roche Ag |
3-indolyl-4-phenyl-1h-pyrrole-2,5-dione derivatives as inhibitors of glycogen synthase kinase-3beta
|
US6482847B2
(en)
*
|
2000-10-03 |
2002-11-19 |
Hoffmann-La Roche Inc. |
Amorphous form of cell cycle inhibitor having improved solubility and bioavailability
|
US6469179B1
(en)
*
|
2000-10-03 |
2002-10-22 |
Hoffmann-La Roche Inc. |
Amorphous form of cell cycle inhibitor having improved solubility and bioavailability
|
US6645970B2
(en)
*
|
2000-11-07 |
2003-11-11 |
Novartis Ag |
Indolylmaleimide derivatives
|
NZ525656A
(en)
*
|
2000-11-07 |
2004-12-24 |
Novartis Ag |
Indolylmaleimide derivatives as protein kinase C inhibitors
|
CA2431166A1
(en)
*
|
2000-12-08 |
2002-06-13 |
Ortho-Mcneil Pharmaceutical, Inc. |
Indazolyl-substituted pyrroline compounds as kinase inhibitors
|
US6548531B2
(en)
*
|
2001-02-09 |
2003-04-15 |
Hoffmann-La Roche Inc. |
Method for cancer therapy
|
DE10109280A1
(de)
*
|
2001-02-26 |
2002-09-05 |
Peter Mayser |
Indolderivate mit inhibitorischer Wirkung auf Proteinkinasen
|
WO2002102373A1
(en)
*
|
2001-06-15 |
2002-12-27 |
F. Hoffmann-La Roche Ag |
Method for administration of cancer therapeutic
|
TW201041580A
(en)
|
2001-09-27 |
2010-12-01 |
Alcon Inc |
Inhibitors of glycogen synthase kinase-3 (GSK-3) for treating glaucoma
|
AU2002342193B2
(en)
*
|
2001-10-29 |
2006-10-26 |
Nektar Therapeutics Al, Corporation |
Polymer conjugates of protein kinase C inhibitors
|
US20030139373A1
(en)
*
|
2001-11-20 |
2003-07-24 |
Breimer Lars Holger |
Method for cancer therapy
|
ATE346070T1
(de)
|
2002-03-05 |
2006-12-15 |
Lilly Co Eli |
Purinderivate als kinaseinhibitoren
|
AU2003217596A1
(en)
*
|
2002-03-08 |
2003-09-22 |
Eli Lilly And Company |
Pyrrole-2, 5-dione derivatives and their use as GSK-3 inhibitors
|
TW200918046A
(en)
|
2002-04-03 |
2009-05-01 |
Novartis Ag |
Indolylmaleimide derivatives
|
AU2003225295A1
(en)
*
|
2002-05-08 |
2003-11-11 |
Janssen Pharmaceutica N.V. |
Substituted pyrroline kinase inhibitors
|
EP1900738A3
(en)
*
|
2002-05-08 |
2008-04-09 |
Janssen Pharmaceutica, N.V. |
Substituted pyrroline kinase inhibitors
|
ES2312785T3
(es)
*
|
2002-06-05 |
2009-03-01 |
Janssen Pharmaceutica Nv |
Pirrolinas sustituidas utiles como inhibidores de quinasa.
|
AU2003238874A1
(en)
|
2002-06-05 |
2003-12-22 |
Janssen Pharmaceutica N.V. |
Bisindolyl-maleimid derivatives as kinase inhibitors
|
CA2393720C
(en)
*
|
2002-07-12 |
2010-09-14 |
Eli Lilly And Company |
Crystalline 2,5-dione-3-(1-methyl-1h-indol-3-yl)-4-[1-(pyridin-2-ylmethyl)piperidin-4-yl]-1h-indol-3-yl]-1h-pyrrole mono-hydrochloride
|
US6800655B2
(en)
*
|
2002-08-20 |
2004-10-05 |
Sri International |
Analogs of indole-3-carbinol metabolites as chemotherapeutic and chemopreventive agents
|
GB0303319D0
(en)
*
|
2003-02-13 |
2003-03-19 |
Novartis Ag |
Organic compounds
|
EP1611132A1
(en)
*
|
2003-03-27 |
2006-01-04 |
Janssen Pharmaceutica N.V. |
Substituted pyrroline kinase inhibitors
|
DE602004016174D1
(de)
*
|
2003-06-13 |
2008-10-09 |
Janssen Pharmaceutica Nv |
Substituierte indazolyl(indolyl)maleimid-derivate als kinase inhibitoren
|
JP2007501774A
(ja)
|
2003-08-08 |
2007-02-01 |
ノバルティス アクチエンゲゼルシャフト |
スタウロスポリンを含む組み合わせ
|
RU2373201C2
(ru)
*
|
2004-01-19 |
2009-11-20 |
Новартис Аг |
Индолилмалеимидные производные
|
US20070232658A1
(en)
*
|
2004-04-08 |
2007-10-04 |
Jurgen Wagner |
Protein Kinase C Inhibitors for the Treatment of Autoimmune Diseases and of Transplant Rejiction
|
EP1765313A2
(en)
|
2004-06-24 |
2007-03-28 |
Novartis Vaccines and Diagnostics, Inc. |
Compounds for immunopotentiation
|
WO2006061212A1
(en)
*
|
2004-12-08 |
2006-06-15 |
Johannes Gutenberg-Universität Mainz |
3-(indolyl)-4-arylmaleimide derivatives and their use as angiogenesis inhibitors
|
KR20070103009A
(ko)
*
|
2005-01-04 |
2007-10-22 |
더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 |
뇌혈류를 증가시키는 방법
|
PL1846406T3
(pl)
*
|
2005-02-09 |
2011-04-29 |
Arqule Inc |
Pochodne imidowe kwasu maleinowego, kompozycje farmaceutyczne i sposoby leczenia nowotworów
|
RU2008104510A
(ru)
*
|
2005-07-11 |
2009-08-20 |
Новартис АГ (CH) |
Производные индолилмалеинимида
|
WO2007027974A1
(en)
*
|
2005-09-02 |
2007-03-08 |
The Board Of Trustees Of The Leland Stanford Junior University |
Method for reducing risk of and extent of injury due to stroke in hypertensive subjects
|
PE20070435A1
(es)
|
2005-09-16 |
2007-06-13 |
Schering Corp |
Formulacion farmaceutica que comprende temozolomida y un inhibidor de la proteina quinasa
|
CA2673368C
(en)
*
|
2006-12-19 |
2014-10-28 |
The Board Of Trustees Of The University Of Illinois |
3-benzofuranyl-4-indolyl maleimides as potent gsk3 inhibitors for neurogenerative disorders
|
JP5490688B2
(ja)
*
|
2007-06-22 |
2014-05-14 |
アークル インコーポレイテッド |
癌の治療のためのインドリルピロリジン
|
CN101801961B
(zh)
*
|
2007-06-22 |
2014-09-24 |
艾科尔公司 |
吡咯烷酮、吡咯烷-2,5-二酮、吡咯烷和硫代琥珀酰亚胺衍生物、组合物以及治疗癌症的方法
|
BRPI0813355A2
(pt)
*
|
2007-06-22 |
2014-12-30 |
Arqule Inc |
Compostos de quinazolinona e métodos de uso dos mesmos
|
FR2927075A1
(fr)
*
|
2008-02-04 |
2009-08-07 |
Centre Nat Rech Scient |
Molecules comprenant un squelette bis-(heteroaryl)maleimide, et leur utilisation dans l'inhibition d'enzymes
|
US8304421B2
(en)
*
|
2008-09-30 |
2012-11-06 |
Vanderbilt University |
Indole compounds and their use as radiation sensitizing agents and chemotherapeutic agents
|
EP2343291A1
(en)
|
2009-12-18 |
2011-07-13 |
Johannes Gutenberg-Universität Mainz |
3-(Indolyl)- or 3-(Azaindolyl)-4-arylmaleimide compounds and their use in tumor treatment
|
EP2338486A1
(en)
|
2009-12-18 |
2011-06-29 |
Johannes Gutenberg-Universität Mainz |
3-(indolyl)- or 3-(azaindolyl)-4-arylmaleimide derivatives for use in the treatment of colon and gastric adenocarcinoma
|
EP2474541A1
(en)
|
2010-12-23 |
2012-07-11 |
Johannes- Gutenberg-Universität Mainz |
Conjugated 3-(indolyl)- and 3-(azaindolyl)-4-arylmaleimide compounds and their use in tumor treatment
|
GB201111427D0
(en)
*
|
2011-07-05 |
2011-08-17 |
Amakem Nv |
Novel bisindolylmaleimides, pan-pkc inhibitors
|
CA2892927A1
(en)
*
|
2012-12-10 |
2014-06-19 |
Centogene Ag |
Use of maleimide derivatives for preventing and treating leukemia
|
WO2014090396A2
(en)
*
|
2012-12-10 |
2014-06-19 |
Centogene Ag |
Use of maleimide derivatives for preventing and treating cancer
|
CN103382199A
(zh)
*
|
2013-06-28 |
2013-11-06 |
北京理工大学 |
一种n-烷基-双吲哚马来酰亚胺的制备方法
|
EP3741375A1
(en)
|
2014-07-17 |
2020-11-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for treating neuromuscular junction-related diseases
|
WO2016207366A1
(en)
|
2015-06-26 |
2016-12-29 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of viral infections
|
EP3187495A1
(en)
|
2015-12-30 |
2017-07-05 |
Johannes Gutenberg-Universität Mainz |
3-(5-fluoroindolyl)-4-arylmaleimide compounds and their use in tumor treatment
|
CN109535158B
(zh)
*
|
2016-04-26 |
2021-04-23 |
浙江工业大学 |
一种双芳基马来酰亚胺类化合物及其药学上可接受的盐及其制备方法和应用
|
US20230203017A1
(en)
*
|
2021-12-28 |
2023-06-29 |
Kamal D. Mehta |
Protein Kinase C Beta Inhibitors and Uses Thereof
|